Compositions and methods of use of interleukin-10 peptides and anti-interleukin-10 antibodies

Abstract

Disclosed herein are methods of reducing a symptom of respiratory disease in a pre-weaned milk-fed mammal by orally administering an isolated antibody that specifically binds the interleukin-10 peptide or an anti-interleukin-10 antibody. Also included are methods of reducing mixing stress in human and non-human mammals by administering an isolated antibody that specifically binds the interleukin-10 peptide or an anti-interleukin-10 antibody. Further included are milk and food compositions including the interleukin-10 peptide or anti-interleukin-10 antibody.

1 . A method of reducing a symptom of respiratory disease in a pre-weaned milk-fed mammal, comprising
 orally administering to the pre-weaned milk-fed mammal an effective amount of an interleukin-10 peptide or an isolated antibody that specifically binds an interleukin-10 peptide,   wherein administration is initiated between birth and weaning, and   wherein administration is performed at least once daily for a period of 7 days to 7 weeks.   
     
     
         2 . The method of  claim 1 , wherein administration of the Il-10 peptide or anti-IL-10 antibody is stopped after the 7 day to 7 week period and is not restarted for 1 to 14 days. 
     
     
         3 . The method of  claim 1 , wherein the pre-weaned milk-fed mammal is of a genus  Bos, Ovis, Capra, Bubalus , or  Sus.    
     
     
         4 . The method of  claim 3 , wherein the pre-weaned milk-fed mammal is a bovine 56 days of age or younger and the respiratory disease is bovine respiratory disease complex. 
     
     
         5 . The method of  claim 4 , wherein the symptom of respiratory disease is elevated rectal temperature, cough, nasal discharge, ocular discharge, ear droop, diarrhea, increased fecal pathogens including  Cryptosporidium parvum , reduced appetite, abnormal attitude, dehydration, reduced weight gain, decreased fecal pH, or a combination thereof. 
     
     
         6 . The method of  claim 1 , wherein the isolated antibody that specifically binds the interleukin-10 peptide is an egg yolk antibody. 
     
     
         7 . The method of  claim 1 , wherein the interleukin-10 peptide or the isolated antibody that specifically binds the interleukin-10 peptide is administered in a milk composition. 
     
     
         8 . The method of  claim 1 , wherein the interleukin-10 peptide is SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, SEQ ID NO. 9, SEQ ID NO. 10, SEQ ID NO. 11, SEQ ID NO. 12, SEQ ID NO. 13, or SEQ ID NO. 14. 
     
     
         9 . A method of reducing mixing stress in a mammal, comprising
 orally administering to the mammal an effective amount of an interleukin-10 peptide or an isolated antibody that specifically binds an interleukin-10 peptide,   wherein administration is initiated within four weeks of mixing the mammal with a new population of mammals, and   wherein administration is performed at least once daily for a period of 7 days to 7 weeks.   
     
     
         10 . The method of  claim 9 , wherein administration of the Il-10 peptide or an isolated anti-IL-10 antibody is stopped after the 7 day to 7 week period and is not restarted for 1 to 14 days. 
     
     
         11 . The method of  claim 9 , wherein the isolated antibody that specifically binds the interleukin-10 peptide is an egg yolk antibody. 
     
     
         12 . The method of  claim 9 , wherein the interleukin-10 peptide or the isolated antibody that specifically binds the interleukin-10 peptide is administered in a food composition. 
     
     
         13 . The method of  claim 9 , wherein the mammal is a non-human mammal. 
     
     
         14 . The method of  claim 13 , further comprising exposing the non-human mammal to a shipping crate, new food, vaccination, branding, tail docking, castration, dehorning, temperature change, a means of transportation, a new handler, a new caregiver, or a combination thereof. 
     
     
         15 . The method of  claim 13 , wherein the interleukin-10 peptide is any one of SEQ ID NOs. 1-34. 
     
     
         16 . A method of reducing mixing stress in a human child, comprising
 orally administering to the human child an effective amount of an interleukin-10 peptide or an isolated antibody that specifically binds an interleukin-10 peptide,   wherein administration is initiated within four weeks of mixing the human child with a new population of human children, and   wherein administration is performed at least once daily for a period of 7 days to 7 weeks.   
     
     
         17 . A milk or formula composition suitable for administration to a pre-weaned mammal of a genus  Bos, Ovis, Capra, Bubalus  or  Sus  comprising a basal milk composition and a therapeutically effective amount of an interleukin-10 peptide or an isolated antibody that specifically binds the interleukin-10 peptide. 
     
     
         18 . The milk composition of  claim 17 , wherein the basal milk composition comprises whole milk, waste milk, or a milk replacer composition. 
     
     
         19 . The milk composition of  claim 17 , wherein the therapeutically effective amount of an interleukin-10 peptide or an isolated antibody that specifically binds the interleukin-10 peptide is 3 g/kg to 0.0001 mg/kg of the milk composition as a dry matter weight. 
     
     
         20 . The milk composition of  claim 17 , wherein the peptide is of any one of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, SEQ ID NO. 9, SEQ ID NO. 10, SEQ ID NO. 11, SEQ ID NO. 12, SEQ ID NO. 13, or SEQ ID NO. 14. or the isolated anti-IL-10 antibody specifically binds a peptide of and one of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, SEQ ID NO. 9, SEQ ID NO. 10, SEQ ID NO. 11, SEQ ID NO. 12, SEQ ID NO. 13, or SEQ ID NO. 14. 
     
     
         21 . The milk composition of  claim 17 , wherein the isolated antibody that specifically binds the interleukin-10 peptide is an egg yolk antibody. 
     
     
         22 . A food composition suitable for administration to a human, comprising a basal food composition and a peptide of SEQ ID NO. 35, SEQ ID NO. 36, SEQ ID NO. 37, or SEQ ID NO. 38; or an isolated anti-IL-10 antibody that specifically binds a peptide of SEQ ID NO. 35, SEQ ID NO. 36, SEQ ID NO. 37, or SEQ ID NO. 38. 
     
     
         23 . The food composition of  claim 22 , wherein the basal food composition is milk, juice, formula, or a solid food consumable by humans. 
     
     
         24 . The food composition of  claim 22 , wherein the isolated antibody that specifically binds the interleukin-10 peptide is an egg yolk antibody.